A novel vascular disrupting agent (NOV202) increases the anticancer efficacy of the PARP inhibitor olaparib in prostate cancer cells with BRCA1/2 mutations

2021 ◽  
Vol 79 ◽  
pp. S608
Author(s):  
E. Sereti ◽  
S. Evans-Axelsson ◽  
S. Rehnmark ◽  
M. Högberg ◽  
A. Bjartell
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Parp Inhibitor ◽  
Prostate Cancer Cells ◽  
Vascular Disrupting Agent ◽  
Anticancer Efficacy ◽  
Vascular Disrupting

scholarly journals Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells

2019 ◽  
Vol 23 (5) ◽  
pp. 312-323 ◽  
Author(s):  
Saman Sargazi ◽  
Ramin Saravani ◽  
Javad Zavar Reza ◽  
Hossein Zarei Jaliani ◽  
Hamidreza Galavi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Parp Inhibitor ◽  
Adenosine Diphosphate ◽  
Prostate Cancer Cells

scholarly journals Efficacy and Mechanism of Action of Marine Alkaloid 3,10-Dibromofascaplysin in Drug-Resistant Prostate Cancer Cells

Marine Drugs ◽  
2020 ◽  
Vol 18 (12) ◽  
pp. 609
Author(s):  
Sergey A. Dyshlovoy ◽  
Moritz Kaune ◽  
Jessica Hauschild ◽  
Malte Kriegs ◽  
Konstantin Hoffer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Anticancer Activity ◽  
Cancer Cells ◽  
Mechanism Of Action ◽  
Synergistic Effects ◽  
Parp Inhibitor ◽  
Cross Resistance ◽  
Drug Candidate ◽  
Prostate Cancer Cells ◽  
Marine Alkaloid

Efficacy and mechanism of action of marine alkaloid 3,10-dibromofascaplysin (DBF) were investigated in human prostate cancer (PCa) cells harboring different levels of drug resistance. Anticancer activity was observed across all cell lines examined without signs of cross-resistance to androgen receptor targeting agents (ARTA) or taxane based chemotherapy. Kinome analysis followed by functional investigation identified JNK1/2 to be one of the molecular targets of DBF in 22Rv1 cells. In contrast, no activation of p38 and ERK1/2 MAPKs was observed. Inhibition of the drug-induced JNK1/2 activation or of the basal p38 activity resulted in increased cytotoxicity of DBF, whereas an active ERK1/2 was identified to be important for anticancer activity of the alkaloid. Synergistic effects of DBF were observed in combination with PARP-inhibitor olaparib most likely due to the induction of ROS production by the marine alkaloid. In addition, DBF intensified effects of platinum-based drugs cisplatin and carboplatin, and taxane derivatives docetaxel and cabazitaxel. Finally, DBF inhibited AR-signaling and resensitized AR-V7-positive 22Rv1 prostate cancer cells to enzalutamide, presumably due to AR-V7 down-regulation. These findings propose DBF to be a promising novel drug candidate for the treatment of human PCa regardless of resistance to standard therapy.

Glucose-regulated protein 78 mediates the anticancer efficacy of shikonin in hormone-refractory prostate cancer cells

Tumor Biology ◽  
2015 ◽  
Vol 36 (7) ◽  
pp. 5063-5070 ◽  
Author(s):  
Li-Jen Kuo ◽  
Chien-Yu Huang ◽  
Wan-Li Cheng ◽  
Chin-Sheng Hung ◽  
Chun-Te Wu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Hormone Refractory Prostate Cancer ◽  
Prostate Cancer Cells ◽  
Anticancer Efficacy ◽  
Hormone Refractory ◽  
Glucose Regulated Protein

scholarly journals MP81-05 CRISPR SCREENING REVEALS GENES DRIVING RESISTANCE AND SENSITIVITY TO PARP INHIBITOR IN PROSTATE CANCER CELLS

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Tomoaki Takai* ◽  
Xiao Bai ◽  
Takuya Tsujino ◽  
Adam Kibel ◽  
Li Jia
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Parp Inhibitor ◽  
Prostate Cancer Cells

scholarly journals A nanoscale, biocompatible and amphiphilic prodrug of cabazitaxel with improved anticancer efficacy against 3D spheroids of prostate cancer cells

2020 ◽  
Vol 1 (4) ◽  
pp. 738-748 ◽  
Author(s):  
Ashok Kumar Jangid ◽  
Deep Pooja ◽  
Poonam Jain ◽  
Sri Vishnu Kiran Rompicharla ◽  
Shwathy Ramesan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Human Prostate ◽  
Human Prostate Cancer ◽  
Prostate Cancer Cells ◽  
Anticancer Efficacy ◽  
3D Spheroids

pH-reponsive and amphiphilic prodrug of cabazitaxel causes greater damages to human prostate cancer cells than free cabazitaxel.

Sign in / Sign up

Export Citation Format

Share Document